Image
A Multimedia Infograph-Edâ„¢ Activity

The Big Picture of IBD

An Interactive Experience Highlighting Recent Clinical Advances

Suggested Readings

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.

Colombel JF, et al. Lancet. 2018;390(10114):2779-2789.

Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.

Coskun M, et al. Pharmacol Res. 2013;76:1-8.

Pathogenesis of inflammatory bowel disease and recent advances in biologic therapies.

Kim DH, Cheon JH. Immune Netw. 2017;17(1):25-40.

The future of Janus kinase inhibitors in inflammatory bowel disease.

De Vries LCS, et al. J Crohns Colitis. 2017;11(7):885-893.

JAK inhibition in inflammatory bowel disease.

Olivera P, et al. Expert Rev Clin Immunol. 2017;13(7):693-703.

Tofacitinib as induction and maintenance therapy for ulcerative colitis.

Sandborn WJ, et al. N Engl J Med. 2017;377(5):496-497.

Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.

Vermeire S, et al. Lancet. 2017;389(10066):266-275.

Activity
The Big Picture of IBD

An Interactive Experience Highlighting Recent Clinical Advances

Relevant Resources

Clinical Updates in Systemic Lupus Erythematosus

Improved Diagnostic and Management Strategies

Advances in Immunosupressive Therapy for Solid Organ Transplantation

Long-Term Management Strategies to Improve Patient Outcomes

Clinical Updates on the Management of Gout

Evidence-Based Strategies for Improved Patient Outcomes

Managing Gout in Primary Care

Evolving Strategies for Diagnosis and Long-Term Management

Improving Outcomes in Rheumatoid Arthritis

Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms

Clinical Updates in Rheumatoid Arthritis

Evolving Treatment Algorithms and Expert Perspectives on Biosimilars

Going Deeper on Atopic Dermatitis

Pathophysiology to the Management of Moderate-to-Severe Disease

BRIDGE HCV

Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV

Looking Beneath The Surface In Atopic Dermatitis

Targeting Immune Dysregulation and Delivering Comprehensive Care

Targeting NASH

Advances in the Diagnosis and Treatment of Nonalcoholic Steatohepatitis

Evolving Treatment Paradigms For Rheumatoid Arthritis

Translating Comprehensive Patient Evaluations Into Personalized Therapy

Hepatitis C is Curable

Got it? Treat it!

Clinical Updates in Rheumatoid Arthritis

New Perspectives on Targeting Remission and Individualizing Therapy

A Better Look at Rheumatoid Arthritis

Using Imaging to Improve Patient Outcomes

BLOCK HIV/HCV

Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.

Clinical Issues in Rheumatoid Arthritis

Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs

The Nexus of NASH and Type 2 Diabetes Mellitus

The Emerging Role of the Diabetologist

Updates in HCV Screening and Treatment

Key Issues Impacting OB/GYN Practice

Pathways to Better Outcomes in Systemic Lupus Erythematosus

Translating Pathophysiology into Targeted Treatments

Clinical Issues in Chronic Liver Disease

Hot Topics in HBV, HCV, and NASH